H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 34 from EUR 32 and keeps a Buy rating on the shares. The firm says the company is “evolving from a single-asset radiotherapy company into a platform-driven biotech through the advancement of its Curadigm Nanoprimer technology.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Updates Share Capital and Voting Rights as of March 31, 2026
- Nanobiotix price target raised to $36 from $26 at Guggenheim
- Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile
- Nanobiotix price target raised to $37 from $26 at Leerink
- Nanobiotix Extends Cash Runway to 2028 as JNJ-1900 Oncology Program Advances and 2025 Results Filed